长按二维码,关注官方公众号
Dr. Chris Lai obtained his Ph.D. at the Novartis-MIT Center, and his research is primarily on dynamic modeling, process optimization, and drug crystallization. With a diverse background in pharmaceuticals and business, Dr. Lai has held positions as Active COO at XtalPi, Consultant in McKinsey, Technical Consultant in General Mills, Technical Consultant in NOVARTIS.
In 2020, he co-founded METiS and served as CEO. As a pioneer in AI-driven drug development, Dr. Lai is at the forefront of leveraging artificial intelligence to revolutionize the process of pharmaceutical research and development. Dr. Lai integrates formulation, delivery technology, and machine learning, laying the foundation for METiS technology platform. Leveraging years of entrepreneurial experience and digital strategies, he steers METiS towards rapid growth.
PANEL DISCUSSION: Decoding Secrets of Modern Medical Innovation
Under the combined effects of policy support, technological progress, and robust demand, the biopharmaceutical industry continues to see emerging opportunities. The sector brings together cutting-edge scientific exploration and attracts considerable capital interest and investment. Scientists’ research is moving from labs to practical applications, benefiting patients. The industry not only needs innovation but also targeted capital investment and effective market integration. Ensuring that these innovations are recognized, supported by capital, and validated by the market is crucial. They should also drive industry advancement while leading to positive societal changes.
